Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
135 Leser
Artikel bewerten:
(0)

New Report Details the Best Practices in Establishing a Clear Corporate Value Proposition

CHAPEL HILL, N.C., March 28, 2014 /PRNewswire/ --The first step in defining a corporate value proposition is clearly identifying how an organization's products and/or services vary from their competitors- or what sets them apart. If a company cannot define a unique characteristic or benefit of their product, customers may default to the most basic option of differentiation - price. For the pharmaceutical industry, defining a clear corporate value proposition is absolutely essential, as playing the low-price game is a lose-lose proposition- even when they make sales.

Although establishing a positive corporate image is critical, the pharmaceutical industry is currently missing out on building corporate image. According to recent primary and secondary research conducted by benchmarking firm, Best Practices, LLC, no pharmaceutical company cracked the top 100 Social Brands list in 2010. Despite this, this does represent a great opportunity for pharmaceutical companies to begin considering how to best present their value proposition to consumers, advocacy groups and health care providers.

The report, "Best Practices in Building Your Corporate Value Proposition," outlines valuable insights and findings from primary and secondary research around the value of building a positive company brand. The study will help corporate leadership to understand the importance of a corporate brand.

Key study topical areas include:

  • Understanding Corporate Value
  • Johnson & Johnson Case Study: Origin On Trust
  • G.E. Healthcare's Healthymagination
  • Eli Lilly Case Study On Social Responsibility
  • Corporate Brand Planning Processes
  • Why Focus On Customer Loyalty?
  • Achieving The Corporate Value Proposition

To access the full report, or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1279.htm.

For more information on other recent primary research studies, contact us at 919.403.0251. For related research, visit our Best Practices, LLC website at http://www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.

SOURCE Best Practices, LLC

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.